Treatment of hypertrophic cardiomyopathy with coenzyme Q10

Hypertrophic cardiomyopathy (HCM) is manifested by severe thickening of the left ventricle with significant diastolic dysfunction. Previous observations on the improvement in diastolic function and left ventricular wall thickness through the therapeutic administration of coenzyme Q10 (CoQ10) in pati...

Full description

Saved in:
Bibliographic Details
Published in:Molecular aspects of medicine 1997, Vol.18 Suppl, p.S145-151
Main Authors: Langsjoen, P H, Langsjoen, A, Willis, R, Folkers, K
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Cardiomyopathy, Hypertrophic - diagnostic imaging
Cardiomyopathy, Hypertrophic - drug therapy
Cardiomyopathy, Hypertrophic - pathology
Coenzymes
Diastole
Digitalis Glycosides - therapeutic use
Diuretics - therapeutic use
Drug Therapy, Combination
Echocardiography
Electron Transport - drug effects
Energy Metabolism - drug effects
Female
Heart Septum - pathology
Heart Ventricles - pathology
Humans
Male
Middle Aged
Treatment Outcome
Ubiquinone - analogs & derivatives
Ubiquinone - therapeutic use
Ventricular Function, Left
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hypertrophic cardiomyopathy (HCM) is manifested by severe thickening of the left ventricle with significant diastolic dysfunction. Previous observations on the improvement in diastolic function and left ventricular wall thickness through the therapeutic administration of coenzyme Q10 (CoQ10) in patients with hypertensive heart disease prompted the investigation of its utility in HCM. Seven patients with HCM, six non-obstructive and one obstructive, were treated with an average of 200 mg/day of CoQ10 with mean treatment whole blood CoQ10 level of 2.9 micrograms/ml. Echocardiograms were obtained in all seven patients at baseline and again 3 or more months post-treatment. All patients noted improvement in symptoms of fatigue and dyspnea with no side effects noted. The mean interventricular septal thickness improved significantly from 1.51 +/- 0.17 cm to 1.14 +/- 0.13 cm, a 24% reduction (P < 0.002). The mean posterior wall thickness improved significantly from 1.37 +/- 0.13 cm to 1.01 +/- 0.15 cm, a 26% reduction (P < 0.005). Mitral valve inflow slope by pulsed wave Doppler (EF slope) showed a non-significant trend towards improvement, 1.55 +/- 0.49 m/sec2 to 2.58 +/- 1.18 m/sec2 (P < 0.08). The one patient with subaortic obstruction showed an improvement in resting pressure gradient after CoQ10 treatment (70 mmHg to 30 mmHg).
ISSN:0098-2997
DOI:10.1016/S0098-2997(97)00006-X